Research Papers:

Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients

Zhibo Tan, Chao Yang, Xiaohan Zhang, Pingju Zheng and Weixi Shen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:60954-60961. https://doi.org/10.18632/oncotarget.17604

Metrics: PDF 1962 views  |   HTML 2450 views  |   ?  


Zhibo Tan1, Chao Yang2, Xiaohan Zhang2, Pingju Zheng1 and Weixi Shen1

1Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, Guangdong, PR China

2Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, Guangdong, PR China

Correspondence to:

Weixi Shen, email: [email protected]

Keywords: GLUT1, meta-analysis, overall survival, prognosis

Received: March 06, 2017    Accepted: April 15, 2017    Published: May 04, 2017


Glucose transporter 1 (GLUT1) plays an important role in the transport and metabolism of glucose in cancer cells. An increasing number of studies have explored the connection between GLUT1 expression and prognosis in non-small cell lung cancer (NSCLC), but the results have been controversial. Therefore, we conducted a meta-analysis to obtain a comprehensive evaluation of the prognostic value of GLUT1 in NSCLC. Relevant studies from PubMed, Embase, and Web of Science were searched. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the effective measures. A total of 10 studies involving 1,665 patients were included in this meta-analysis. The results showed that GLUT1 overexpression was associated with poor overall survival (HR = 2.21; 95% CI, 1.42–3.42; p < 0.001) and disease-free survival (HR = 1.73; 95% CI, 1.35–2.23; p < 0.001). Furthermore, elevated GLUT1 expression correlated with sex (OR = 2.29; 95% CI, 1.17–4.49; p = 0.015), advanced tumor stage (OR = 2.46; 95% CI, 1.79–3.38; p < 0.001), histology (OR = 6.99; 95% CI, 4.71–10.38; p < 0.001), and large tumor size (OR = 2.77; 95% CI, 1.73–4.44; p < 0.001). This meta-analysis revealed overexpression of GLUT1 to be a biomarker of worse prognosis in NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17604